Included with registration, selection made during registration process.


Thursday, February 28 12:30 – 2:00pm (non-CME)
CytoSorb Therapy – New Options to Regain Control in Hyperinflammation and Septic Shock
Chairs: C. Ronco/Italy and L. Forni/UK


  • JL Vincent/BE
    Shock reversal in septic shock – what can we do if we fail with SMT
  • C Ince/NL
    Influence on microcirculation and vascular barrier function
  • S Mitzner/D
    Combination of CytoSorb with different blood purification therapies – why and when does it make sense

Friday, March 1 6:45-8:00am (non-CME)

The Novel Biomarker Proenkephalin: The Emerging Role and Clinical Utility in Kidney Function
sponsored by Sphingotec
Proenkephalin as a biomarker of kidney function, is distinguishing itself as a “real time” reflection of renal function. Currently available markers are too late, are influenced by comorbidities such as inflammation or indicate renal damage versus function. Proenkephalin enables early prediction, diagnosis and monitoring of acute kidney injury (AKI) in order to assess kidney function of critical ill patients – including AHF patients. With over 25,000 patients accrued through clinical studies, this novel biomarker is clearly emerging as an asset in the assessment of kidney function in both acute and chronic settings. The distinguished faculty at this symposia will present some of the most recent study data in the growing body of evidence supporting Proenkephalin in clinical care.


Urine Flow rate and its use as a Biomarker in Critical Care
sponsored by Renal Sense
The session will cover the potential of urine flow as an early indicator of AKI, and as a realtime parameter for response to the therapy, and for local and systemic disease.


  • John Kellum, MD
  • Robert Safirstein, MD